ArticleBiological trace element research2022
Protective Effect of Lactobacillus sporogenes against Arsenic-Induced Hematological Alterations in Male Albino Wistar Rats.
Article in Biological trace element research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Myricetin ameliorates arsenic-induced hematological changes, immune dysfunction, oxidative stress, hepatic and renal injuries and promotes inflammatory genes in rats.Open veterinary journal · 2024Article
- Phosphate Uptake and Its Relation to Arsenic Toxicity in Lactobacilli.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to evaluate the arsenic-induced hemotoxicity and to evaluate the protective effects of Lactobacillus sporogenes in male albino Wistar rats. A total of 36 adult male albino Wistar rats were procured and divided into 3 groups of 12 animals each. Group 1 rats served as control, group 2 rats were administered sodium arsenite (@5 mg/kg BW/day), groups 3 rats were supplemented with L. sporogenes (@15 million spores/kg BW/day) along with sodium arsenite administered along with sodium arsenite orally daily for 28 consecutive days. Weekly body weights, hematological profile, and erythrocyte morphology were assessed. Significant (P < 0.05) reduction in mean weekly body weights (g) was observed in group 2 than group 1; however, a significant (P < 0.05) increase in weekly body weights was observed in group 3 as compared to group 2. A significant (P < 0.05) decrease in erythrocyte-related parameters and platelet counts, and a significant (P < 0.05) leukocytosis, relative lymphopenia, absolute neutrophilia, and monocytosis were noticed among arsenic-treated rats when compared to the control group. Blood smear of arsenic-treated rats contains echinocytes, microcytes, and spherocytes when compared to control. Scanning electron microscopic examination of blood revealed altered erythrocyte morphology in arsenic-treated rats with poikilocytosis and blebbing of the erythrocyte membrane. Supplementation of L. sporogenes along with arsenic resulted in improvement of all the hematological parameters and reduction in morphological abnormalities in comparison to the toxic control group. It is concluded that supplementation of L. sporogenes can effectively alleviate the arsenic-induced hematological alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.